SG11201909206XA - Macro-encapsulated therapeutic cells and methods of using the same - Google Patents

Macro-encapsulated therapeutic cells and methods of using the same

Info

Publication number
SG11201909206XA
SG11201909206XA SG11201909206XA SG11201909206XA SG 11201909206X A SG11201909206X A SG 11201909206XA SG 11201909206X A SG11201909206X A SG 11201909206XA SG 11201909206X A SG11201909206X A SG 11201909206XA
Authority
SG
Singapore
Prior art keywords
international
methods
macro
pct
applicant
Prior art date
Application number
Inventor
William L Rust
Original Assignee
Seraxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seraxis Inc filed Critical Seraxis Inc
Publication of SG11201909206XA publication Critical patent/SG11201909206XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04—Alginic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules

Abstract

caE ! o o o Therapeutic d - eyice implanted ° Trisulin pellet implanted Insulin pellet removed nduction of diabetes 130 190 Days (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT 111111E1mo 1E1 oio llmonolomon oili 1o11 ono °El (10) International Publication Number WO 2018/186953 Al (51) International Patent Classification: A61P 5/48 (2006.01) A61L 27/38 (2006.01) A61L 27/20 (2006.01) A61L 27/54 (2006.01) (21) International Application Number: PCT/US2018/020446 (22) International Filing Date: 01 March 2018 (01.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/482,413 06 April 2017 (06.04.2017) US (71) Applicant: SERAXIS, INC. [US/US]; 20271 Goldenrod Lane, #2085, Germantown, Maryland 20876 (US). (72) Inventor: RUST, William L.; c/o SERAXIS, INC., 20271 Goldenrod Lane, #2085, Germantown, Maryland 20876 (US). (74) Agent: SCHORR, Kristel et al.; FOLEY & LARDNER LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: MACRO-ENCAPSULATED THERAPEUTIC CELLS AND METHODS OF USING THE SAME Figure 4 0 (57) : Described are macro-capsules and barriers that can be used to prepare therapeutic cell implants, methods of encapsulating N therapeutic cells, and methods of using the encapsulated cells in the treatment of disease. C [Continued on next page] WO 2018/186953 Al MIDEDIMOMMIDEFIE31110111HEIMOVOIS Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201909206X 2017-04-06 2018-03-01 Macro-encapsulated therapeutic cells and methods of using the same SG11201909206XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482413P 2017-04-06 2017-04-06
PCT/US2018/020446 WO2018186953A1 (en) 2017-04-06 2018-03-01 Macro-encapsulated therapeutic cells and methods of using the same

Publications (1)

Publication Number Publication Date
SG11201909206XA true SG11201909206XA (en) 2019-11-28

Family

ID=61764135

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909206X SG11201909206XA (en) 2017-04-06 2018-03-01 Macro-encapsulated therapeutic cells and methods of using the same

Country Status (12)

Country Link
US (1) US20180289746A1 (en)
EP (1) EP3606613A1 (en)
JP (1) JP7293126B2 (en)
KR (1) KR102572188B1 (en)
CN (1) CN110709137A (en)
AU (1) AU2018250008A1 (en)
BR (1) BR112019020611A2 (en)
CA (1) CA3058369A1 (en)
IL (1) IL269817B1 (en)
RU (1) RU2019131719A (en)
SG (1) SG11201909206XA (en)
WO (1) WO2018186953A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169089A1 (en) * 2018-03-01 2019-09-06 Seraxis, Inc. Macro-encapsulated therapeutic cells, devices, and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743545A (en) * 1984-08-09 1988-05-10 Torobin Leonard B Hollow porous microspheres containing biocatalyst
US5545423A (en) * 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5334640A (en) * 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
CA2149420C (en) * 1992-11-16 2007-04-17 Frank T. Gentile Microporous macrocapsules
US7427415B2 (en) * 2002-10-11 2008-09-23 Novocell, Inc. Implantation of encapsulated biological materials for treating diseases
US20080292690A1 (en) * 2006-04-07 2008-11-27 Technology Center Multi-membrane immunoisolation system for cellular transplant
US20070237749A1 (en) 2006-04-07 2007-10-11 Wang Taylor G Multi-membrane immunoisolation system for cellular transplant
US9540630B2 (en) * 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
KR101096902B1 (en) * 2009-01-15 2011-12-22 가톨릭대학교 산학협력단 Islet microcapsule of alginate-chitosan bilayer for treating diabetes mellitus and process for preparing the same
AU2012237375A1 (en) * 2011-03-29 2013-10-10 Beta-Cell Nv Method for encapsulated therapeutic products and uses thereof
KR101373518B1 (en) * 2011-04-28 2014-03-13 서울대학교산학협력단 Capsulated pancreatic islet and process for preparing the same
JP6538042B2 (en) * 2013-11-07 2019-07-03 ザ ジェネラル ホスピタル コーポレイション Elution matrix and its use
US9408807B2 (en) * 2015-01-13 2016-08-09 Taylor Gun-Jin Wang Semi-permeable encapsulation system with tapered conduits for diabetes reversal
JP2018521717A (en) * 2015-05-17 2018-08-09 マサチューセッツ インスティテュート オブ テクノロジー Multilayer hydrogel capsules for encapsulating cells and cell aggregates

Also Published As

Publication number Publication date
AU2018250008A1 (en) 2019-10-31
US20180289746A1 (en) 2018-10-11
JP7293126B2 (en) 2023-06-19
IL269817B1 (en) 2024-03-01
BR112019020611A2 (en) 2020-04-22
KR102572188B1 (en) 2023-08-30
CN110709137A (en) 2020-01-17
KR20190133708A (en) 2019-12-03
JP2020512999A (en) 2020-04-30
WO2018186953A1 (en) 2018-10-11
IL269817A (en) 2019-11-28
EP3606613A1 (en) 2020-02-12
CA3058369A1 (en) 2018-10-11
RU2019131719A (en) 2021-05-06

Similar Documents

Publication Publication Date Title
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201807187XA (en) Binding members to pd-l1
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201809751XA (en) Egfr inhibitor compounds
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201909009TA (en) Catheter securement device with window
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201805942UA (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201908042TA (en) Smartcard
SG11201804721SA (en) Modulators of complement activity
SG11201805001UA (en) Method of treating influenza a
SG11201810618QA (en) Depot formulations
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases